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Only minority of infants with recurrent or persistent
respiratory symptoms will develop asthma. The develop-
ment of asthma is associated with Th1- and Th2-cell
activity imbalance. Increased levels of Th1 activation
marker, serum soluble CD26 (sCD26), and Th2 activation
marker, serum soluble CD30 (sCD30) have been found in
asthmatic adults and school children. Whether these
markers are of clinical use in infants with troublesome
lung symptoms has not been evaluated before.
Altogether 43 children aged 4 to 26 months with persis-
tent cough, recurrent wheeze, or shortness of breath were
investigated clinically and randomized to receive either
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budesonide 400 ug/day or placebo for 6 weeks. There were
no differences in baseline data like gender, atopic traits,
clinical findings, or whole body plethysmography measure-
ments between these two intervention groups. At baseline,
serum sCD26 and sCD30 levels did not differ between the
intervention groups. After the 6-week intervention there
was a significant decrease in sCD30 levels in atopic (i.e.
skin prick test positive and/or having atopic eczema) chil-
dren treated with budesonide (p=0.028), and in non-atopic
children who received placebo (p=0.008), but no changes
in sCD30 levels in atopic children treated with placebo
(p=0.753), or in non-atopic children treated with budeso-
nide (p=0.695) (Fig.1). As regards sCD26, a significant
increase was seen between the levels measured before and
after the 6-week intervention (p=0.012), but the increase
was independent of the type of the intervention.
In conclusion, Th1-type immunity is suppressed and
Th2-type immunity activated in infants with troublesome
lung symptoms. However, only atopic infants may benefit
of anti-inflammatory inhalants.
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